Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
You may also be interested in...
Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.
EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least.